Why Baxter International Stock Was Tumbling Today
Key Points
Its final quarter of 2025 was mixed, with a notable whiff on earnings.
On the plus side, it notched a convincing beat on revenue.
- 10 stocks we like better than Baxter International ›
Sprawling medical devices and technology company Baxter International (NYSE: BAX) looked like it needed some medicine and a little rest on Thursday. The company's shares were down 17% in mid-session trading, on the back of an earnings report that many investors found lackluster.
A flop in the final quarter
Baxter's fourth quarter of 2025 saw total sales rise 8% year over year to $2.97 billion. The company's net income from continuing operations not in accordance with generally accepted accounting principles (GAAP), however, slumped by 24% to $225 million ($0.44 per share).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
This shook out into a mixed quarter, as analysts tracking Baxter were collectively modeling only $2.84 billion for sales, but a notably higher $0.54 per share non-GAAP (adjusted) net income from continuing operations figure.
In its earnings release, Baxter admitted that this performance did not meet its expectations.
It pledged that recently introduced changes to its operating model hold the promise of, in the words of CEO Andrew Hider, "bringing us closer to our customers and ultimately helping us to improve our say-do ratio and execute more consistently."
Slow improvement?
That turnaround might not be around the corner, however. Baxter provided guidance for the entirety of 2026 forecasting flat to 1% sales growth relative to 2025. Adjusted net income from continuing operations is estimated at $1.85 to $2.05 per share for the year, comparing unfavorably to 2025's $2.27.
While I think Baxter has generally been an effective purveyor of many medical products and technologies, this strategic shift would concern me if I were a shareholder.
A big question mark is when, and even if, it'll start to have a positive and lasting impact on the company's business. I'd be wary of Baxter stock for that reason.
Should you buy stock in Baxter International right now?
Before you buy stock in Baxter International, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Baxter International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,165,045!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 12, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
